Published in Vaccine Weekly, October 7th, 2009
"We had a very successful year in terms of revenues generated by our base Animal Health business, experiencing 21% growth in a challenging global economy," said Graeme McRae, Chairman, President CEO of Bioniche Life Sciences Inc. "In addition, subsequent to the end of the fiscal year, we announced a transformative corporate event: The signing of a licensing agreement with Endo Pharmaceuticals Inc. for exclusive rights to develop and market UrocidinTM in the U.S. with an option for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.